Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Depreciation & Amortization (CF) (2016 - 2025)

Altimmune (ALT) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $27000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 27.03% to $27000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $119000.0, a 62.7% decrease, with the full-year FY2024 number at $238000.0, down 50.1% from a year prior.
  • Depreciation & Amortization (CF) was $27000.0 for Q3 2025 at Altimmune, down from $30000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $285000.0 in Q3 2021 to a low of -$552000.0 in Q3 2023.
  • A 5-year average of -$33105.3 and a median of $37000.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 291.02% in 2021, then plummeted 1052.83% in 2023.
  • Altimmune's Depreciation & Amortization (CF) stood at $117000.0 in 2021, then plummeted by 301.71% to -$236000.0 in 2022, then soared by 148.31% to $114000.0 in 2023, then crashed by 71.05% to $33000.0 in 2024, then dropped by 18.18% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Depreciation & Amortization (CF) are $27000.0 (Q3 2025), $30000.0 (Q2 2025), and $29000.0 (Q1 2025).